Many cancer patients in India face 70-75% out-of-pocket expenses despite having health insurance. Policies often struggle to keep up with the high cost of modern treatments, targeted therapies, and non-hospitalization expenses, creating a significant financial burden for families.
For many Indian families, the promise of health insurance is often tested when faced with a diagnosis as serious as cancer. While policies are intended to provide a financial safety net, recent trends show that patients are frequently forced to pay 70-75% of their total treatment costs from their own savings. This mismatch between the coverage amount and the actual medical bills is becoming a pressing financial challenge for households across the country.
The Reality of Coverage Gaps
The gap in protection stems from how many health insurance policies are structured. While a policy might offer a total sum insured—for instance, ₹5 lakh—the actual payout for cancer treatment is often limited by specific sub-limits. These are predefined caps on how much an insurer will pay for specific services, such as chemotherapy sessions, radiation therapy, or hospitalization room rent. When these caps are set low, the remaining amount falls squarely on the patient.
Furthermore, many insurance plans do not account for modern medical advancements. Treatments like targeted therapies, which are becoming standard for various cancers, are often excluded or classified in ways that make reimbursement difficult. In some instances, these life-saving drugs are administered on an outpatient basis, meaning the patient does not need to stay in the hospital. Since many traditional insurance policies only trigger payment upon 24-hour hospitalization, these outpatient expenses are often entirely denied, leaving families to bear the full cost.
Challenges with Next-Generation Therapies
Medical experts have pointed out that the shift toward advanced cancer care is the primary driver of these rising costs. Treatments such as immunotherapy and oral targeted therapies are highly effective but come with a steep price tag, sometimes costing over a lakh for a single dose. Government schemes like Ayushman Bharat PM-JAY do provide some support, with coverage up to ₹5 lakh annually, but this limit is often insufficient for advanced or recurring cancer cycles where total costs can easily exceed ₹20-30 lakh.
Oncologists note that insurance providers often use technical exclusions to limit claim approvals. This leads to a complex cycle where families, already dealing with the emotional toll of a diagnosis, must navigate lengthy reimbursement procedures. The reliance on 'cashless' facilities is also frequently hampered by the need for prior authorization or disputes over which specific treatments are covered under the policy terms.
Financial Impact and What to Monitor
For households, this systemic issue means that health insurance is often not the comprehensive shield it appears to be. Financial planning for healthcare now requires a deeper look at policy documents beyond just the total sum insured.
Investors and consumers should track whether insurance providers begin to offer more specific cancer riders or modular policies that explicitly cover newer treatment methods. As the healthcare sector continues to innovate with expensive next-generation drugs, the ability of insurers to update their products will be critical. Moving forward, the key monitorable for patients is checking for comprehensive coverage that includes outpatient care, diagnostic tests, and specific sub-limits for oncology treatments, rather than relying solely on base health insurance policies.